Known as "completely changing the pattern of China's pharmaceutical market", the collection has created a number of domestic pharmaceutical companies.
On April 7, Huiyu Pharmaceutical released the 2021 annual performance report showing that the company's operating income was 1.827 billion yuan, an increase of 33.69% over 2020, and the net profit was 445 million yuan, an increase of 30.% year-on-year. The reason is that Huiyu Pharmaceutical said that a number of products were selected in the fifth batch of the country, which made the performance grow rapidly.
After three years of collection, the industry bearishness has been gradually released. According to the statistics of the Health Bureau, a number of domestic pharmaceutical companies such as Huiyu, Huahai, Qilu and CSPC have expanded their market share.
Of course, there are also industry leaders who are "tight cursed" by the national drug collection. Hengrui Pharmaceutical has repeatedly said in the performance report that it has been affected by the loss of bids and the price reduction of winning bids, and its stock price has fallen by more than 50% since June last year, and its market value has evaporated by nearly 300 billion yuan.
Relying on the "barefoot" participation in the collection of profits, Huiyu Pharmaceutical began to transfuse blood to research and development in turn. According to the annual report, in 2021, Huiyu Pharmaceutical invested 250 million yuan in new drug research and development, and implemented the phased strategy of "combining imitation and innovation with innovation".
There is no eternal darkness in the pharmaceutical industry, only the dawn that has not yet reached.
Three years of sales of 1 billion yuan, relying on exclusive bids to seize the market
Using the rules of national drug collection, a number of pharmaceutical companies seized market share, and the company's performance continued to rise.
According to the financial report, in 2021, the revenue of Huiyu Pharmaceutical's pemetrexed disodium for injection was 1.447 billion yuan, accounting for 79.49% of the company's main business income, which is the company's main source of income and profit.
The Health Bureau was informed that the injection of pemetrexed disodium has continued to win the bid in the Guangdong Alliance, the winning price of 599 yuan (100mg) per bottle, while also in Jiangsu also continued to win the bid, the product price of 525 yuan per bottle, the rest of the region before the introduction of the new bidding plan, are continued according to the original selected enterprises.
Huiyu Pharmaceutical believes that with the gradual advancement of consistency evaluation and the gradual increase of market competitors, pemetrexed disodium for injection is facing the risk of a significant decline in performance.
Pemetrexed is a large variety commonly used in clinical practice, mainly used for malignant pleural mesothelioma. According to data from the Intranet, in 2017, the sales of urban public hospitals nationwide were 4.182 billion yuan, and the original research manufacturers Eli Lilly, Howsen and Qilu held nearly 80% of the market share. Huiyu's products were only approved for listing in September 2017, and after facing the market for a year, the sales revenue in 2018 was only 28.3253 million yuan, and the company was forced to hand over the products to a third party for promotion.
The turning point appeared in the national collection. During the 4+7 collection pilot, Huiyu Pharmaceutical's injection of pemetrexed disodium was the only generic drug in the country that had been evaluated, and it competed with the original research manufacturer Eli Lilly, and the result was that Eli Lilly lost the bid and Huiyu won the bid. Although Eli Lilly subsequently won the bid to catch up with it during the 4+7 expansion, Huiyu has opened up the hospital market through collection:
From 82 hospitals at the end of 2018, it surged to 1206 at the end of 2019, and sales also soared to 656 million yuan.
Just in the first year of the national collection, Huiyu Pharmaceutical successfully counterattacked and firmly laid the status of the jianghu. Although Eli Lilly, Howsen, Qilu, and Jisme have entered the national or provincial level collection at a reduced price, it has been unable to stop Huiyu Pharmaceutical from rapidly occupying the market.
In 2020, the number of hospital terminal sales of Huiyu Pharmaceutical increased to 2444, and the operating income of a single product exceeded 1 billion yuan, and more importantly, Huiyu Pharmaceutical has firmly occupied the initiative of the Pemetroxed market.
The national drug collection has allowed Huiyu Pharmaceutical to taste the policy dividend, even if the market starts from scratch, the collection and collection has the opportunity to let the pharmaceutical factory overturn.
Huiyu Pharmaceutical also has 5 products included in the third and fifth batches of collection. According to the financial report, in 2021, azacitidine for injection will achieve revenue of 105 million yuan in 2021, an increase of 487.69% over 2020; the overall revenue of docetaxel will reach 150 million, an increase of 64.68% over 2020.
The market war has just begun, and small and medium-sized pharmaceutical companies have staged a counterattack myth
Unlike mature large pharmaceutical companies, Huiyu Pharmaceutical is a typical "barefoot" enterprise.
As a result, in just a few years, riding on the east wind of the collection, Hui Yu put on his shoes. In 2017, Huiyu Pharmaceutical's annual revenue was only 13.98 million yuan, and by 2021, this figure will surge to 1.8 billion yuan.
Today, Basically Shore's Huiyu Pharmaceutical has begun to deploy R&D innovations. The annual report discloses that the company currently has 10 first-class innovative drug projects under research, including 4 biological innovative drugs and 6 chemical innovative drugs.
A pharmaceutical company may be able to rely on a single variety to counterattack, but it must not rely on a single variety to eat for a lifetime. The Health Bureau combed and found that since 2020, the pemetrexed disodium for injection of Yangtze River, Hengrui Pharmaceutical, Chia Tai Tianqing and Qilu Pharmaceutical has passed the consistency evaluation. Huiyu Pharmaceutical also admitted in its annual report that the company's products were affected by competitors and there will be an adverse impact on sales declines in the future.
In the past three years, it is far more than just the Huiyu family that has enjoyed the harvesting dividend.
On March 22, CSPC Pharmaceutical Group released its annual report that its revenue in 2021 was 27.867 billion yuan, an increase of 11.7% year-on-year. Gein's national drug collection has enabled a number of newly listed generic drugs to be selected, and the rapid release of quantity has brought a new round of sales contribution. Among them, pramipexole hydrochloride tablets are the first Parkinson's disease treatment drugs of CSPC Pharmaceutical Group, which won the bid collection in February 2021, and achieved a sales revenue increase of 172% in that year.
Kelun Pharmaceutical also strives to obtain a share of the public hospital market through national drug collection. In the fifth batch of national collection in 2021, Kelun won the bid for a total of 11 products, and the number of winning bids was the first in the industry, becoming one of the leading suppliers of national collection and procurement. Pharmaceutical companies such as Chia Tai Tianqing have also seized the policy dividend of national drug collection and procurement to increase market share.
The national drug collection is changing the pattern of China's pharmaceutical market. Any small and medium-sized enterprise with technical strength and cost reduction is likely to become a dark horse, seize the market share of public hospitals, and make the sales kingdom built by large pharmaceutical companies in the past few decades overturn in an instant.
Many pharmaceutical giants can not continue to survive, Hengrui, Xinlitai, Huadong Pharmaceutical core products lost the bid, there was a decline in performance, and turned to the road of transformation and innovation.
Analysts pointed out that the collection is a double-edged sword, on the one hand, it provides more market space for domestic pharmaceutical companies, on the other hand, it also gives pharmaceutical companies with weak research and development capabilities huge price pressure, and promotes the transformation of pharmaceutical companies with serious product homogenization.
Wen | Lei Gong operated | twenty-thirteen
#Domestic innovative pharmaceutical companies ##汇宇制药 #